Welichem Biotech Inc. is a drug discovery and early-stage drug development company. The Company focuses on new therapeutics for autoimmune/inflammatory diseases and cancers. The Company is dedicated to research and development of its anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. All the Company�s drug candidates are derived from the metabolites of bacterial symbionts of soil living nematodes. Using its Symbiochem technology platform, the Company has developed a robust pipeline of compounds that target various diseases, including inflammatory diseases and cancers. WBI-1001 targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. On July 31, 2012, the WBI-1001 technology was acquired by Stiefel, a Glaxo Group Limited (GSK) company.